Equillium Inc (NASDAQ:EQ) stock plunged 12.4% following the company’s announcement that it will integrate cryptocurrency ...

Investing.com -- Equillium Inc (NASDAQ: EQ) stock tumbled 12.4% after the biotechnology company announced plans to integrate cryptocurrency into its treasury reserve strategy, a significant deviation ...

As the U.S. markets react to recent economic uncertainties, including weak job reports and tariff concerns, investors are reassessing their strategies amid fluctuating indices. In this context, penny ...

Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates Equillium (EQ) delivered earnings and revenue surprises of 106.67% and 69.98%, respectively, for the quarter ended June 2024.

Equillium expects to begin enrolling patients in an alopecia areata Phase 2 study of EQ101 in the fourth quarter of 2022. EQ102 is a bi-specific cytokine inhibitor that selectively targets IL-15 ...

--Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the completion of an End-of-Phase 1 meeting ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet ...

--Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced favorable topline data from the Type A group ...

Equillium said 83% of the participants enrolled in the study achieved complete or partial response, and about two-thirds had a 80% reduction in urine protein creatinine ratio by week 28.